Evotec Rides Megatrend In Outsourced Innovation By Buying Aptuit CRO
Executive Summary
Evotec's CEO tells Scrip that by buying the CRO Aptuit his combined group becomes a one-stop-shop for drug makers who are increasingly outsourcing their innovation efforts.
You may also be interested in...
Evotec Leverages Infectious Diseases Space With Sanofi R&D Deal
Evotec's CEO tells Scrip its pact with Sanofi to develop an infectious disease pipeline could offer a commercially viable approach to battling the global AMR crisis.
Deal Watch: CSL Behring's Calimmune Buy Builds On Its Base & Adds Platform Tech
Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.
Big Pharma CEOs Suggest Policy Changes As They Return To Beijing
Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.